SAGE-324, also known as BIIB124, is an experimental drug. It is a neurosteroid that works as a GABA<sub>A</sub> receptor positive allosteric modulator.
SAGE-324 was being developed by Biogen for the treatment of essential tremor. Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.